November 29, 2021
Eli Lilly’s JAK inhibitor Olumiant (baricitinib) was granted sakigake fast-track designation for the treatment of type I interferon-mediated autoinflammatory diseases, the health ministry said on November 26. The designation was given for the indication of “type I interferon-mediated autoinflammatory diseases...read more